Eupraxia Pharmaceuticals (TSE:EPRX) has released an update.
Eupraxia Pharmaceuticals is set to unveil results from its Phase 2 SPRINGBOARD study on an osteoarthritis knee treatment at the prestigious EULAR European Congress of Rheumatology in Vienna. The presentation will detail the efficacy of their long-acting intra-articular injection, EP-104IAR, showcasing its potential to meet a significant unmet medical need. The company’s innovative DiffuSphere technology promises targeted, extended-release drug delivery, aiming to provide patients with prolonged relief and minimal side effects.
For further insights into TSE:EPRX stock, check out TipRanks’ Stock Analysis page.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
